Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 35Recurrence 9Neoplasms 3Sarcoma, Kaposi 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Immunoglobulin Light-chain Amyloidosis 1Chromosome 17 deletion 1Alzheimer Disease 1Acquired Immunodeficiency Syndrome 1

Interventions

Azacitidine 11venetoclax 8decitabine and cedazuridine drug combination 6Tacrolimus 4Decitabine 4Cyclophosphamide 4fludarabine phosphate 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Injections 3Cytarabine 3Busulfan 3Biopsy 3ruxolitinib 2itacitinib 2fludarabine 2Whole-Body Irradiation 2Vorinostat 2Specimen Handling 2Sirolimus 2Mycophenolic Acid 2Lenalidomide 2CPX-351 2veliparib 1tagraxofusp 1spartalizumab 1seclidemstat 1sabatolimab 1quizartinib 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myelomonocytic, Chronic × pomalidomide × Clear all
NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled 12 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡